These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22306350)

  • 21. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
    Kupryś-Lipińska I; Kuna P
    Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Airway remodeling in asthma: new mechanisms and potential for pharmacological intervention.
    Girodet PO; Ozier A; Bara I; Tunon de Lara JM; Marthan R; Berger P
    Pharmacol Ther; 2011 Jun; 130(3):325-37. PubMed ID: 21334378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of severe asthma with anti-immunoglobulin E (Omalizumab). A new possibility in pulmonary medicine].
    Nolte H; Harving H; Backer V
    Ugeskr Laeger; 2007 Dec; 169(50):4366-7. PubMed ID: 18211797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The increasing challenge of discovering asthma drugs.
    Mullane K
    Biochem Pharmacol; 2011 Sep; 82(6):586-99. PubMed ID: 21745459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
    Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
    J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotypes and endotypes of uncontrolled severe asthma: new treatments.
    Campo P; Rodríguez F; Sánchez-García S; Barranco P; Quirce S; Pérez-Francés C; Gómez-Torrijos E; Cárdenas R; Olaguibel JM; Delgado J; ;
    J Investig Allergol Clin Immunol; 2013; 23(2):76-88; quiz 1 p. follow 88. PubMed ID: 23654073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
    Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
    Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma.
    Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Bodzenta-Lukaszyk A
    Respiration; 2010; 80(6):534-42. PubMed ID: 20588001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of monoclonal antibodies and related agents in the treatment of respiratory disease.
    Schachter EN; Neuman T
    Drugs Today (Barc); 2009 Jul; 45(7):533-48. PubMed ID: 19834630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omalizumab: overview of pharmacology and efficacy in asthma.
    Ledford DK
    Expert Opin Biol Ther; 2009 Jul; 9(7):933-43. PubMed ID: 19527111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Badly controlled severe persistent asthma: an additional new treatment].
    Nomémie L; Verpilleux MP; Ballouard K
    Soins; 2006 Dec; (711):19-21. PubMed ID: 17274408
    [No Abstract]   [Full Text] [Related]  

  • 33. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment.
    Peters SP; Ferguson G; Deniz Y; Reisner C
    Respir Med; 2006 Jul; 100(7):1139-51. PubMed ID: 16713224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omalizumab: new drug. Asthma: too many unknowns for an anti-IgE.
    Prescrire Int; 2007 Oct; 16(91):179-82. PubMed ID: 17926440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omalizumab for severe asthma?
    Drug Ther Bull; 2006 Nov; 44(11):86-8. PubMed ID: 17089921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Many asthma patients experience persistent symptoms despite appropriate clinical and guideline-based treatment with inhaled corticosteroids.
    Mogil J
    J Am Acad Nurse Pract; 2007 Sep; 19(9):459-70. PubMed ID: 17760570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-IgE and other antibody targets in asthma.
    Singh J; Kraft M
    Handb Exp Pharmacol; 2008; (181):257-88. PubMed ID: 18071950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
    Nowak D
    Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The future of asthma therapy].
    Solèr M
    Schweiz Med Wochenschr; 2000 Feb; 130(8):277-81. PubMed ID: 10726286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Role of monoclonal anti-IgE antibodies (rhu-MAb) in the treatment of allergic bronchial asthma].
    Targowski T; From S
    Pol Merkur Lekarski; 2003 Jan; 14(79):65-8. PubMed ID: 12712834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.